KRAS and cancer: Furthermore, several clinical trials are underway for several SHP2 inhibitors, such as JAB-3068, RLY-1971, SHP099 and TNO155, either as monotherapy or in combination with KRAS (G12C) inhibitors, EGFR inhibitors, SOS-1 or RAF inhibitors, demonstrating the potential of targeting SHP2 to combat adaptive reactivation of KRAS in cancer (NCT04330664, NCT04185883, NCT04699188, NCT04973163, and NCT04975256).